Future research should investigate whether mCRP accumulates in pancreatic or vascular tissues in T1D, whether its levels correlate with disease duration or microvascular complications, and whether modulating CRP dissociation (e.g., via agents like C10M) could offer therapeutic benefit in T1D-related vascular dysfunction. This evidence concerns the gene CRP and type 1 diabetes mellitus.